ad image

Company Info

Mylan

Mylan

Drug Discovery & Development

Overview

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which approximately 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at www.mylan.com/investors.

Mylan
Contributions
24 Contributions1 / 2
Mylan
Donation

Mylan and Sesame Workshop Partner to Provide Socio-Emotional Support Resources to Families Impacted by COVID-19

Mylan

PR-M08-20-NI-22Aug 14, 2020
Mylan
COVID-19 Treatment

Mylan to Supply Investigational Antiviral Remdesivir for the Potential Treatment of COVID-19

Mylan

PR-M05-20-NI-018May 14, 2020
Mylan
Leadership

Mylan Board Appoints Robert J. Coury As Executive Chairman

Mylan

PR-M04-20-NI-026Apr 17, 2020
Mylan
M&A

Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn

Mylan

PR-M03-20-NI-041Mar 26, 2020
Mylan
Legal Settlement

Mylan Finalizes Previously Disclosed Settlement with U.S. Securities and Exchange Commission

Mylan

PR-M09-19-NI-060Sep 30, 2019
Mylan
Recall

Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter

Mylan

PR-M03-19-NI-050Mar 19, 2019
Mylan
FDA Approval

Mylan Announces FDA Approval of Wixela™ Inhub™, First Generic of ADVAIR DISKUS®

Mylan

PR-M02-19-NI-005Feb 05, 2019
Mylan
Launch

Launch of Generic Lialda® Delayed-Release Tablets Expands Mylan's Gastroenterology Product Offering

Mylan

PR-M01-19-NI-001Jan 02, 2019
Mylan
Gastroenterology

Mylan Expands Gastroenterology Portfolio with Launch of Generic for Prevacid® SoluTab Delayed-Release Orally Disintegrating Tablets

Mylan

PR-M12-18-NI-022Dec 07, 2018
Mylan
FDA Inspection

Mylan Statement in Response to FDA Warning Letter Relating to Morgantown Plant

Mylan

PR-M11-18-NI-093Nov 27, 2018
Mylan
Recall

Mylan Initiates Voluntary Nationwide Recall Due to the Detection of Trace Amounts of NDEA

Mylan

PR-M11-18-NI-087Nov 26, 2018
Mylan
Biosimilars

Mylan and Biocon Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab

Mylan

PR-M10-18-NI-071Oct 22, 2018
Mylan
Clinical Data

Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting

Mylan

PR-M10-18-NI-038Oct 11, 2018
Mylan
Biosimilar

Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim

Mylan

PR-M09-18-NI-087Sep 27, 2018
Mylan
Generics

Mylan Launches Authorized Generic of Ampyra® Tablets

Mylan

PR-M09-18-NI-089Sep 27, 2018
Mylan
Generics

Mylan Launches First Generic for Adcirca® Tablets

Mylan

PR-M09-18-NI-021Sep 10, 2018
Mylan
Biosimilar

Mylan and Fujifilm Kyowa Kirin Biologics Announce Positive CHMP Opinion for Hulio™, Biosimilar Adalimumab

Mylan

PR-M08-18-NI-001Aug 01, 2018
Mylan
Drug Development

Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon® Patch

Mylan

PR-M07-18-NI-028Jul 10, 2018
Mylan
HIV

Mylan Introduces Symfi™ Triple Combo Once-Daily HIV Treatment in the U.S.

Mylan

PR-M03-18-NI-111Mar 30, 2018
Mylan
Drug Development

Mylan to Introduce Two New Cost-Saving HIV Combination Treatments in the U.S.

Mylan

PR-M03-18-NI-023Mar 07, 2018
1 / 2
0 Contributors1 / 0

No authors found

1 / 0